Aegis starts Revance at Buy with 60% upside

• Aegis Capital initiates coverage on Revance Therapeutics (RVNC -0.3%) with a Buy rating and $28 (60% upside) price target.
• The company's lead product candidate is RT002 (daxibotulinumtoxinA for injection) for the treatment of frown lines. In a mid-stage study, RT002 beat Allergan's (AGN +2.2%) BOTOX Cosmetic.